CA-PEGASUS-TECH
10.3.2021 13:02:13 CET | Business Wire | Press release
Pegasus Tech Ventures (“Pegasus”), a global venture capital firm based in Silicon Valley, announced a partnership with Japan’s television shopping giant Japanet Holdings (“Japanet”) to establish a $50 million corporate venture capital fund to invest in innovative startups around the globe.
Japanet, headquartered in Nagasaki, Japan, is well-known for its home shopping services and now is expanding into other business sectors. The company recently started a new project to build “Stadium City” in Nagasaki, Japan, which will open in 2024. Centered on a sports stadium, the project includes the development of mixed-use facilities such as business offices, retail stores, hotels, and live event arenas, aiming to make it a Nagasaki landmark that will revitalize the local and regional community. Japanet is also committed to the enrichment of elderly life and to providing educational support for children around the globe.
Through the fund with Pegasus, Japanet aims to create value by funding new ideas and collaborating with startups that develop innovative technologies. The fund plans to invest in Silicon Valley and other parts of North America, as well as in Israel, Europe and Asia.
“We at Japanet Group would like to find high-potential startups with talented entrepreneurs and help them succeed and contribute real value to the world. Using a venture fund, we would like to find cutting edge startup technologies that we can use in the Nagasaki 'Stadium City' project, so that we can provide new services, such as child education, elder care, hospitality, and other services that can help with the betterment of people’s lives,” said Akito Takata, President and CEO of Japanet.
"We will leverage our global network to introduce Japanet to top-tier startups,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures. “By making the connection, both the startups and Japanet benefit. Our goal is to create a global innovation platform that supports the growth of our portfolio companies and the success of our corporate partners.”
Pegasus will deploy its team in Silicon Valley and in 15 other regions around the world to find the best startups and connect them with Japanet and Pegasus’ extensive network of corporate partners.
Pegasus has established venture investment funds with over 35 global corporations, including Aisin Seiki, Sojitz Corporation, SEGA SAMMY HOLDINGS, Sunny Health, CAC Holdings Corporation, Teijin Limited, Infocom Corporation, Innotech Corporation, and ASUS, among others.
About Japanet Holdings Co., Ltd.
Based on a corporate vision, "The joy of living now," Japanet operates a home shopping business, as well as a major sports related business designed to revitalize the local and regional community. In order to enrich the "now," Japanet is also working to enhance healthcare services and to address other social issues, such as educational support for children around the world, and support for disaster-stricken areas. For more information, please visit the website https://corporate.japanet.co.jp/ .
About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Some of the 35+ corporate partners that have signed up to work with Pegasus include ASUS, Aisin, SEGA, Sojitz, and Omron. These corporations are able to have access to 180+ Pegasus portfolio companies such as SpaceX, 23andMe, SoFi, Bird, Color, App Annie, and many more. To learn more, visit www.pegasustechventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom